Sutro Biopharma (NASDAQ:STRO) Given Buy Rating at HC Wainwright
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $12.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 315.22% from the stock’s current price. A […]
More Stories
Stryker Co. (NYSE:SYK) Shares Sold by Meeder Advisory Services Inc.
Meeder Advisory Services Inc. cut its stake in Stryker Co. (NYSE:SYK – Free Report) by 3.4% in the third quarter,...
Meeder Advisory Services Inc. Purchases 42 Shares of S&P Global Inc. (NYSE:SPGI)
Meeder Advisory Services Inc. raised its stake in shares of S&P Global Inc. (NYSE:SPGI – Free Report) by 0.8% during...
Investment Analysts’ Recent Ratings Updates for Allogene Therapeutics (ALLO)
Allogene Therapeutics (NASDAQ: ALLO) has recently received a number of price target changes and ratings updates: 11/14/2024 – Allogene Therapeutics...
Cisco Reports 4th Consecutive Revenue Decline, Looks to AI for Growth Revival
By Panos Mourdoukoutas Cisco Systems is well positioned to capitalize on the opportunity in artificial intelligence (AI) to revive sales...
Wirtual (WIRTUAL) Trading Up 83.8% Over Last Week
Wirtual (WIRTUAL) traded 4.2% lower against the U.S. dollar during the 1 day period ending at 12:00 PM E.T. on...
Wanchain 1-Day Volume Hits $2.35 Million (WAN)
Wanchain (WAN) traded 0.3% lower against the US dollar during the one day period ending at 12:00 PM ET on...